Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $4.67 Volume: 54,711
Change: $-0.15 % Change: -3.11%
Day High/Low: 4.84/4.51 52 Week High/Low: 10.36/2.50
Last Traded: April 27, 2015 11:47 Transaction Volume: 200
Open: 4.82 Previous Close: 4.82
Bid: 4.55 Ask: 4.70
Bid Size: 1700 Ask Size: 300
Market Cap: 50.7m Shares Out: 10.9m
PE Ratio: 1.3 Dividend Yield: N/A

Opinion

More insiders buying Novo Research (T.NRI), Stockhouse poster says

Stockhouse members have their say as we feature today’s Top Poster, Bullboard, and Blog, and recognize noteworthy contributions from our community.

Stockhouse Editorial   December 19, 2014
0 stars

Leading growth stocks in the market today (BIIB) (ALXN) (AAPL)

Stockhouse members have their say as we feature today’s Top Poster, Bullboard, and Blog, and recognize noteworthy contributions from our community.

Stockhouse Editorial   March 26, 2014
0 stars

Nuvo Research's (T.NRI) shareholders react to latent FDA approval – stocks slip 21%

Gaalen Engen   January 17, 2014
0 stars

Junior energy stock pops on Pacific Rubiale investment

While gold/silver drill results grabbed the attention of some speculators Monday

Sean Mason   May 28, 2012
0 stars

Latest Bullboard Posts

  • RE:Horizon and P2

    0 stars

    That PR by Horizon  says a lot about the quality of P2. In my opinion, we should have much better leverage negotiating P2 rights in...

    2 stars


  • Dan,john and others

    0 stars

    Just receive notice of annual meeting, and well...administrators are very well rewarded. We can't tell the same for the shareholders who...

    1.5 stars


  • RE:RE:RE:RE:Breaking above $5

    0 stars

    they say they are positive results WF10 but want to abandon the project ... It is not clear. ?? Why stop WF10

    2 stars


  • Horizon and P2

    0 stars

    News > Press Releases Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of...

    2.5 stars


  • RE:RE:RE:RE:Breaking above $5

    0 stars

    Agreed but that is the problem when you let lawyers draft press releases. As far as best choices for voting at this AGM - DO NOT vote...

    4.5 stars